Combo Rx for fibromyalgia tied to higher adherence
(HealthDay)—Medication adherence is better for combination prescription initiators with fibromyalgia syndrome (FMS), although expenditures for total health care are higher with combination prescriptions, according to a study published online April 18 in Pain Practice.
Nicole M. Marlow, Ph.D., from the University of Florida in Gainesville, and colleagues examined medication adherence and health care costs for combination prescription initiators (duloxetine/milnacipran/venlafaxine with pregabalin; 100 patients) versus monotherapy initiators (duloxetine, milnacipran, venlafaxine, and pregabalin; 1,771 patients combined) among patients with FMS. Claims data for the South Carolina Blue Cross Blue Shield State Health Plan were evaluated.
The researchers found that the odds ratios for high adherence were significantly increased (P < 0.05) among the combination cohort versus the venlafaxine (2.15), duloxetine (1.39), and pregabalin (2.20) cohorts. For the combination cohort, expenditures for total health care were significantly higher (P < 0.05) versus duloxetine ($26,291 versus $17,190), milnacipran ($33,638 versus $22,886), and venlafaxine ($26,586 versus $16,857) cohorts.
"Our findings suggest important clinical benefits with the use of combination prescription therapy, and prospective studies of medication adherence are warranted to examine causal relationships with outcomes not captured by health care claims databases," the authors write.
More information:
Abstract
Full Text (subscription or payment may be required)
Copyright © 2017 HealthDay. All rights reserved.
